Profitability Metrics

Gross Margin
21.77%
Operating Margin
13.78%
Net Margin
9.81%

Efficiency Metrics

Revenue per Expense Ratio
1.16
R&D as % of Revenue
0.00%

Earnings Quality

EBITDA Margin
20.32%
Income Tax Rate
24.54%
EPS
8.4100000000

Balance Sheet Analysis

Current Ratio
2.57
Cash Ratio
0.90
Working Capital
$1.99B
Debt to Equity
0.79
Debt to Assets
36.55%
Equity Ratio
46.05%

Cash Flow Analysis

Operating Cash Flow Ratio
16.86%
Free Cash Flow Ratio
10.80%
CapEx to Revenue
6.05%
Dividends Paid
$448.90M
Stock Buybacks
$41.50M
Total Shareholder Returns
$490.40M
Cash Position Change
102.50%

Key Takeaways (2023 FY)

  • Revenue declined by 7.9688605803255%, indicating potential market challenges
  • Increased dividend payments by 10.64%

Detailed Growth Metrics

Core Performance

Revenue
-7.97%
Net Income
-25.69%
EPS
-23.04%
Operating Income
9.88%

Operational Efficiency

R&D Expenses
0.00%
SG&A Expenses
-4.55%
Operating Cash Flow
-12.03%
Free Cash Flow
26.03%

Balance Sheet Health

Assets
8.46%
Debt
13.61%
Book Value per Share
12.92%
Inventory
3.66%

Shareholder Returns

Dividends per Share
10.64%
Shares Outstanding
-3.47%

Long Term Trends

3Y Revenue/Share
23.76%
5Y Revenue/Share
16.90%
3Y Dividend/Share
58.24%
5Y Dividend/Share
75.98%